Privilège Ventures

Privilège Ventures Research

Investment Thesis

Privilège Ventures is Switzerland's first female-led venture capital firm, dedicated to backing bold, ambitious, and resilient founders driving breakthrough innovations across HealthTech, CleanTech, and AgriFoodTech sectors. The firm invests with conviction, believing that diverse, high-performing teams with visionary leadership deliver superior returns and meaningful impact. Their investment thesis is grounded in the data-backed conviction that gender-mixed teams and women-led companies demonstrate better performance outcomes, using economic rationale rather than purely fairness arguments to support their investment focus.

Founded with over five decades of combined experience in finance, entrepreneurship, and management across the investment team, Privilège Ventures combines deep scientific and technical expertise with hands-on operational support. The firm is FINMA-authorized and brings a transgenerational perspective to early-stage investing.

Sector Focus

Privilège Ventures explicitly focuses on three interconnected sectors:

HealthTech: Diagnostic devices, health monitoring solutions, and medical technologies. Portfolio includes companies like Avelo (respiratory diagnostics), Gondola Medical (surgical robotics), Levy Health (fertility diagnostics), and Distal Motion (surgical automation).

CleanTech & Sustainability: Environmental solutions, sustainable agriculture, and climate-positive innovations. Companies like Inergio (energy solutions) and Agro Sustain represent this focus.

AgriFoodTech: Agricultural innovation and food tech solutions that combine sustainability with innovation. Focus on founder-first approach with scientific rigor.

Across all sectors, the firm has notable investments in security (Keyless - biometric authentication), advanced materials (Adiposs, Enantios), hardware and IoT (IDUN Technologies - brain-sensing earbuds), and analytics (BioSpectal, Annaida - clinical diagnostics).

Stage Focus

Privilège Ventures invests primarily from Pre-Seed through Series A, with a particular emphasis on:

• Pre-Seed: Founders with vision and early product validation
• Seed: Early traction and product-market fit indicators
• Series A: Proven business models ready to scale

The firm is thesis-driven and collaborative, aiming to be a strategic partner rather than a passive investor. They take active roles in governance and strategic decisions while keeping founders in the driver's seat.

Check Size

Based on the disclosed information:

• Historical range: CHF 100,000 - CHF 1,000,000 (approximately $115k - $1.15M USD)
• Focus: Early-stage companies with pre-seed to Series A financing needs

The fund size of CHF 20M suggests checks within the typical early-stage VC range, with flexibility based on the founder and opportunity quality.

Fund Status and Recent Activity

Privilège Ventures Fund I (CHF 20M) is actively deploying capital with recent 2024-2025 activity:

Recent Portfolio Wins and Milestones:

• Adiposs: Secured CHF 4M Series A (June 2025), recognized as one of Switzerland's most innovative companies
• Annaida: Selected as top 13 finalist for ZKB Pionierpreis Technopark 2025, closing pre-Series A funding
• Keyless: Raised $2M for AI deepfake prevention (January 2025), ranked among top 50 facial recognition algorithms globally in NIST FRVT evaluations
• IDUN Technologies: Launched groundbreaking brain-sensing earbuds at CES 2025
• Sonix: Won CHF 850k Innosuisse grant for AI audio communication development
• Hydromea: Announced strategic partnerships for subsea WLAN technology deployment

Portfolio Company Scale: Multiple companies demonstrating significant growth - Smeetz expanding across Europe, Scantrust winning Unilever Brand Challenge.

Lead Tendency

Based on portfolio composition and thesis description, Privilège Ventures demonstrates a both/partnership model:

• Often leads early-stage rounds where they can provide strategic value
• Participates in later rounds (Series A+) alongside other investors
• Takes structured governance roles in portfolio companies
• Builds long-term partnerships with founders

Portfolio Highlights

Portfolio Size: 25+ active portfolio companies across HealthTech, CleanTech, and AgriFoodTech

Notable Companies by Sector:

• HealthTech: Avelo (respiratory diagnostics), Gondola Medical (surgical robotics), Levy Health (women's fertility), Distal Motion (surgical automation), BioSpectal (clinical diagnostics), Annaida (clinical tech)
• Security/Biometrics: Keyless (AI-powered biometric authentication and deepfake prevention)
• Hardware/IoT: IDUN Technologies (brain-sensing wearables), Cyltronic (IoT solutions)
• Advanced Materials/Chemistry: Adiposs (specialty materials), Enantios (biotech materials)
• Agriculture: Agro Sustain (sustainable agriculture)
• Consumer/Services: Smeetz (booking platform), Byhours (accommodation services), Scantrust (supply chain authentication)

Team

Leadership:

• Jacqueline Ruedin Rüsch - General Partner, driving the firm's vision and strategy
• Angelica Morrone - General Partner, co-leading investment and portfolio support

Extended Team:

• Nicole Schimenti - Community manager (Google background), building investor and founder network
• Mershad Javan, Cesare Pezzini, Haena Kim - Investment team members
• Didier Denat, Marco Nannini, Ypatios Moysiadis, Elisabeth Aloy, Sarah Clatterbuck - Advisors bringing deep industry and operational expertise

Firm Culture: The team emphasizes authenticity, dedication, discipline, and goal-orientation. Decision-making is described as empathic, consensual, and collegial. The firm champions transparency, teamwork, respect, and ethical values.

Decision Process

Based on public information:

• Structure: Partnership-based with structured investment committee
• Approach: Empathic and consensual decision-making
• Governance: Clear ownership with two GPs providing strong leadership
• Process: Disciplined, structured investment evaluation with rigor and excellence
• Timeline: Standard early-stage VC timelines, though not explicitly stated

Geographic Focus

Primary: Switzerland (Lugano-based, Swiss-focused) Secondary: Across Europe with emphasis on Switzerland

The firm explicitly states: "Investing across Europe, with a focus on Switzerland, we support gender mixed startups from pre-seed to Series A."

Founder Preferences

Based on investment thesis and portfolio:

• Diverse founding teams with mixed gender representation
• Bold and ambitious entrepreneurs with transformative vision
• Resilient founders capable of navigating challenges
• Technical depth combined with business acumen (evident from HealthTech/CleanTech focus)
• Mission-driven founders solving real problems in health, sustainability, and food
• Founders with operational experience and willingness to collaborate with experienced partners

The firm explicitly backs "gender mixed startups," recognizing that diversity improves outcomes.

Co-Investor Network

Based on portfolio activity:

• Works alongside other Swiss and European venture firms
• Collaborates on Series A rounds with larger investors
• Partners with grant programs (Innosuisse) to support portfolio companies
• Engages with EU-level funding (Horizon Europe, EIC programs)

Notable Patterns

1. Science-Forward Investing: Many portfolio companies have strong scientific foundations (medical devices, biotech, diagnostics)
2. Hardware Comfort: Significant allocation to hardware companies (IDUN, Enantios, Adiposs, Gondola Medical)
3. Switzerland Concentration: Strong representation of Swiss startups despite pan-European mandate
4. Active Support: Portfolio updates suggest hands-on engagement and governance participation
5. Impact Focus: Climate, health, and sustainability themes align with global impact trends
6. Female-Led/Mixed Teams: Stated commitment reflected in portfolio composition

Investment Community Engagement

The firm actively builds community through:

• Regular discovery trips and site visits to research institutions
• Curated events bringing together investors, founders, and experts
• Network access for portfolio companies and limited partners
• Knowledge-sharing through blog/insights content
• CEO appearances at industry conferences and award ceremonies (Jacqueline Ruedin Rüsch named among top 100 Europe's most influential women in VC for two consecutive years)

Unique Differentiators

1. Female-Led Structure: Only Swiss female-led dedicated venture fund at launch
2. Scientific Rigor: Deep expertise in life sciences and technical validation
3. Experienced Team: Over 100 years combined financial and strategic leadership experience
4. Disciplined Approach: Empathic but structured decision-making
5. Long-Term View: Managing assets over multiple cycles with focus on lasting value creation
6. Community Integration: Strong focus on ecosystem building beyond just capital provision